CCCC Q3 2020 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$239M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+57.5% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$18M-217.2% margin

Net Income

-$22M-258.5% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

-12.6%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$436,000

Balance Sheet

Total Assets

$229M

Total Liabilities

$385M

Stockholders' Equity

-$156M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$5M	+57.5%
Gross Profit	$8M	-$8M	+211.4%
Operating Income	-$18M	-$10M	-83.5%
Net Income	-$22M	-$10M	-116.3%